Market research
4BSB.F 4basebio AG
F EUR Healthcare
Latest close
Latest stored close unavailable
Test a moving-average rule with historical data.
Market facts
- Market cap
- 93M
- P/E ratio
- 1.54
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.74
Profile
Instrument facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- Not available
- Market cap
- 93M
- P/E ratio
- 1.54
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.74
About
About 4basebio AG
4basebio AG, an enabler of advances in medical science and patient care, focuses on manufacturing DNA products for therapeutic and other uses in Europe, the United States, and internationally. It also focuses on providing research and diagnostic products based on its RNA reverse transcriptase, DNA polymerase, and DNA primase enzymes, addressing the research tools and diagnostic products markets. The company was formerly known as Expedeon AG and changed its name to 4basebio AG in January 2020. 4basebio AG is based in Heidelberg, Germany.
Research context
4basebio AG appears in PyInvesting’s Frankfurt Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the 4BSB.F discussion.
5 years, 7 months ago
4basebio AG is currently in a long term downtrend where the price is trading 6.0% below its 200 day moving average.
From a valuation standpoint, the stock is 94.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 77.4.
4basebio AG's total revenue sank by 93.0% to $289K since the same quarter in the previous year.
Its net income has dropped by 518.5% to $-1M since the same quarter in the previous year.
Finally, its free cash flow fell by 652.0% to $-925K since the same quarter in the previous year.
Based on the above factors, 4basebio AG gets an overall score of 1/5.